Velagliflozin 

Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Velagliflozin (1 mg/kg; p.o.; single dose) increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats^[1].
Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

395.45

Oil

C₂₃H₂₅NO₅

946525-65-1

O[[email protected]]1[[email protected]](C2=CC(CC3=CC=C(C4CC4)C=C3)=C(C#N)C=C2)O[[email protected]](CO)[[email protected]@H](O)[[email protected]@H]1O

Room temperature in continental US; may vary elsewhere.

• [1]. Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273.  [Content Brief]

  [2]. Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655.  [Content Brief]